Literature DB >> 28971751

Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.

Irbaz Bin Riaz1, Umar Zahid1, Muhammad Umar Kamal2, Muhammad Husnain1, Ali McBride3, Anh Hua4, Auon Abbas Hamadani1, Laeth George5, Ali Zeeshan6, Qurat-Ul-Ain Riaz Sipra1, Ammad Raina7, Bushra Rahman5, Soham Puvvada1, Faiz Anwer1.   

Abstract

Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.

Entities:  

Keywords:  chimeric antigen T cells; hematological malignancy; leukemia; lymphoma; refractory; relapse

Mesh：

Substances：

Year:  2017        PMID： 28971751      PMCID： PMC6040074          DOI： 10.2217/imt-2017-0062

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  43 in total

1.  Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Authors:  Christian S Hinrichs; Zachary A Borman; Lydie Cassard; Luca Gattinoni; Rosanne Spolski; Zhiya Yu; Luis Sanchez-Perez; Pawel Muranski; Steven J Kern; Carol Logun; Douglas C Palmer; Yun Ji; Robert N Reger; Warren J Leonard; Robert L Danner; Steven A Rosenberg; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-24       Impact factor: 11.205

2.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

3.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 4.  Chimeric antigen receptor modified T cell therapy for B cell malignancies.

Authors:  Cameron J Turtle
Journal:  Int J Hematol       Date:  2013-12-14       Impact factor: 2.490

5.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

6.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

7.  Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.

Authors:  Helene M Finney; Arne N Akbar; Alastair D G Lawson
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

8.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

9.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors:  V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

10.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Authors:  Jennifer N Brudno; Robert P T Somerville; Victoria Shi; Jeremy J Rose; David C Halverson; Daniel H Fowler; Juan C Gea-Banacloche; Steven Z Pavletic; Dennis D Hickstein; Tangying L Lu; Steven A Feldman; Alexander T Iwamoto; Roger Kurlander; Irina Maric; Andre Goy; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Frances T Hakim; Steven A Rosenberg; Ronald E Gress; James N Kochenderfer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544
View more
  8 in total

Review 1.  Adoptive cell therapies in thoracic malignancies.

Authors:  Julie Lasvergnas; Marie Naigeon; Kader Chouahnia; Laurent Zelek; Nathalie Chaput; Boris Duchemann
Journal:  Cancer Immunol Immunother       Date:  2022-02-07       Impact factor: 6.630

2.  Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis.

Authors:  Xiao-Hong Zheng; Xi-You Zhang; Qian-Qian Dong; Feng Chen; Shou-Bo Yang; Wen-Bin Li
Journal:  Chin Med J (Engl)       Date:  2020-01-05       Impact factor: 2.628

3.  Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.

Authors:  Komal Adeel; Nathan J Fergusson; Risa Shorr; Harold Atkins; Kevin A Hay
Journal:  Syst Rev       Date:  2021-01-21

Review 4.  Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches.

Authors:  Tanja Fetter; Dennis Niebel; Christine Braegelmann; Joerg Wenzel
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

Review 5.  Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study.

Authors:  Mohsen Sheykhhasan; Hamed Manoochehri; Paola Dama
Journal:  Cancer Gene Ther       Date:  2022-01-05       Impact factor: 5.854

Review 6.  Lessons to cancer from studies of leukemia and hematopoiesis.

Authors:  Geoffrey Brown
Journal:  Front Cell Dev Biol       Date:  2022-09-20

7.  Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.

Authors:  Genmao Cao; Lijian Lei; Xiaolin Zhu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

8.  Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.

Authors:  Jia Wang; Nan Mou; Zhenxing Yang; Qing Li; Yanyu Jiang; Juanxia Meng; Xuxiang Liu; Qi Deng
Journal:  Br J Haematol       Date:  2020-03-31       Impact factor: 6.998
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.